Patent intelligence · US
US 11040027
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
Patent details — US 11040027
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 22, 2021
- Expiration
- Jun 17, 2041
- Applicant
- HEPAREGENIX GMBH
- Claims
- 15
- CPC classes
- A61K, A61K31/437, A61K31/501, A61P
Quick answer
US 11040027 (Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death) is held by HEPAREGENIX GMBH. Status: granted. Granted Jun 22, 2021. Expires Jun 17, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HEPAREGENIX GMBH
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/437, A61K31/501, A61P, A61P1/16
More from HEPAREGENIX GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11040027?
US 11040027 (Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death) is held by HEPAREGENIX GMBH. Status: granted. Granted Jun 22, 2021. Expires Jun 17, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11040027?
HEPAREGENIX GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11040027 expire?
Our index shows an expiration date of Jun 17, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.